This review aims to explore the critical challenges in the management of BRAF-mutated NSCLC, providing a comprehensive summary of the current evidence and highlighting ongoing clinical trials that aim to address these critical gaps. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.